Pitfalls of Founding a Life Science Company: Invention, Patenting, Development, and Regulatory Challenges and What we Can be Done in Washington DC to Make Things Better-Peter G. Milner, MD, FACC-07/12/2011 - 6:00pm

Event Information
Event Topic: 
Pitfalls of Founding a Life Science Company: Invention, Patenting, Development, and Regulatory Challenges and What we Can be Done in Washington DC to Make Things Better
Event Date: 
07/12/2011 - 6:00pm
Event Location: 
Wilson Sonsini Goodrich & Rosati- 650 Page Mill Road, Palo Alto, CA
Speaker Information
Event Speaker: 
Peter G. Milner, MD, FACC
Event Speaker Title: 
Co-Founder and Executive VP Corporate Development
Event Speaker Company: 
Optivia Biotechnology and Co-founder CV Therapeutics, ARYx Therapeutics and ML Labs.
Event Speaker Bio: 

Peter G. Milner, MD, FACC, Co-Founder and Executive VP Corporate Development Optivia Biotechnology and Co-founder CV Therapeutics, ARYx Therapeutics
In 2007 Peter co-founded Optivia Biotechnology, a private company now recognized as a leader in the emerging field of transporter biology, where he serves as executive vice president corporate development. In 1997 Peter co-founded ARYx Therapeutics (NASDAQ:ARYX) where he served as CEO until 2005, and President from 2005 to 2010 with overall responsibility for R&D. In 1990 he co-founded CV Therapeutics (NASDAQ:CVTX), where as a member of senior management from 1992-1996 he in-licensed and co-invented several successful pharmaceuticals. CV Therapeutics was acquired by Gilead for $1.5B in cash in 2009. In 2005, Peter was instrumental in restructuring his family pharmaceutical company ML Laboratories (MLB.LSE) and its subsequent merger to form Vectura (VEC.LSE), a profitable company and one of the worlds leading makers of inhaled products.
Prior to 1992, Peter was as an assistant professor of medicine at Washington University in St. Louis. His research led to the discovery of pleiotrophin (PTN), a novel growth factor that regulates stem cell differentiation, organ development, and the epithelial mesenchymal transition (EMT). He was educated at the University of Liverpool receiving his medical degree in 1980, before completing his postgraduate training at Johns Hopkins Hospital, The University of Virginia, and Washington University in St. Louis. Peter is co-inventor on 48 issued patents, and an author of 28 original scientific articles in Science, Biochemistry, Circulation, Cancer, JCI, and JBC. He is a Fellow of the American College of Cardiology (FACC), and a board certified physician and cardiologist. He serves as adjunct clinical faculty at Stanford University School of Medicine, and as a board member of the California Healthcare Institute (CHI).

Event Details
Cost: 
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Event Details: 

'

Payment Dec 12th Evening Event - $20 to TheGeneral Public

Attention B2DG members: You must login to your account first to see the members' early-bird admission rate.
If you are not a B2DG member or if you had missed the early-bird deadline, the registration fee is $20. Please follow these instructions to register.

We use PAYPAL to process your online payment. Print and bring a copy of your online receipt with you. If space permits, walk-ins are welcomed; please be prepared to pay $25 at the door (cash or check). There is no refund, exchange, or transfer. Thank you for your cooperation.
To register now, please select your meal preference from the pull-down menu below and enter the attendee's information. Then click on the "Pay Now" button to reach the PayPal payment page. Each attendee must be registered separately.
Make sure you enter the attendee's meal choice, name, and email address.


Meal Choice
Name of Attendee
Email Address